(Q40270389)

English

Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation?

scientific article published on November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Trends in the prescribing of oral agents for the management of type 2 diabetes mellitus in the United States, 1990-2001: does type of insurance influence access to innovation? (English)

1 reference

Europe PubMed Central

19 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

author name string

Tracy L Skaer

1

1 reference

Europe PubMed Central

19 September 2017

David A Sclar

2

1 reference

Europe PubMed Central

19 September 2017

Linda M Robison

3

1 reference

Europe PubMed Central

19 September 2017

publication date

1 November 2006

1 reference

Europe PubMed Central

19 September 2017

The Science of Diabetes Self-Management and Care

1 reference

Europe PubMed Central

19 September 2017

32

1 reference

Europe PubMed Central

19 September 2017

940-953

1 reference

Europe PubMed Central

19 September 2017

6

1 reference

Europe PubMed Central

19 September 2017

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Economic costs of diabetes in the US in 2002.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s. Achievements and future developments

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Evaluation of a self-administered sensory testing tool to identify patients at risk of diabetes-related foot problems.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Pharmacologic therapy for type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Comparative tolerability profiles of oral antidiabetic agents

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Prescribing behaviour in clinical practice: patients' expectations and doctors' perceptions of patients' expectations--a questionnaire study

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Pharmaceuticals in Medicare reform

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

The impact of cost-effectiveness on public and private policies in health care: an international perspective. Introduction and overview

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Socioeconomic differences in Medicare supplemental coverage

1 reference

https://api.crossref.org/works/10.1177%2F0145721706295021

21 January 2018

Identifiers

10.1177/0145721706295021

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40270389&oldid=1487983493"